C-PLM2

FILE C-PLM2·COMPANY·CURATED BY ETERNAL SEARCH

712 North Inc

mitochondrial medicine, AI discovery, bifurcated stress response

modulatingsmall molecule

712north.com·San Francisco, California, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-PLM2

Projects

OMA1 high-throughput screening assay

exploratory

platform · medium

Enable scalable discovery of OMA1 activators and inhibitors for mitochondrial disease-relevant drug screening.

Cellular OMA1 protease assay using an engineered luciferase reporter targeted to the mitochondrial inner membrane, where reporter signal inversely correlates with OMA1 activity.

Published high-throughput screen reported validation of the reporter assay and identification of both OMA1 activators and inhibitors.

The screen found that kinase inhibitors can activate OMA1 and demonstrated that the assay can detect compounds modulating OMA1 activity.

OMA1 inhibitor discovery program

preclinical

drug program · high

Identify OMA1 inhibitors as potential cytoprotective medicines for disorders influenced by dysfunctional mitochondria, including heart failure and Alzheimer's disease.

Small-molecule drug discovery targeting the mitochondrial inner-membrane protease OMA1 and its OPA1/DELE1 stress-signaling pathway.

Published review describes OMA1 inhibitors as needed drug-like tools and potential medicines, with prior screening efforts reported by multiple groups.

OMA1 inhibition is described as promising based on genetic ablation data in ischemia-reperfusion-related disease models, but potent inhibitors remain a development need.

OPA1 pathway therapeutic strategy for Autosomal Dominant Optic Atrophy

exploratory

research program · medium

Assess therapeutic approaches for Autosomal Dominant Optic Atrophy caused primarily by OPA1 mutations and clarify translational challenges for mitochondrial neurodegeneration.

Review and evaluation of OPA1-pathway therapeutic strategies, including gene augmentation, small molecules, antisense approaches for OPA1 haploinsufficiency, and alternative neuroprotective targets.

2026 publication reviews 25 years from OPA1 gene discovery to therapeutic strategy and notes that antisense therapies targeting OPA1 haploinsufficiency are under human safety evaluation.

The review identifies lack of robust clinical endpoints, variable slow progression, and developmental retinal ganglion cell loss as major challenges for late-stage intervention.

Personalized mitochondrial medicines for age-related diseases

undisclosed

platform · medium

Develop personalized mitochondrial medicines for age-related diseases by targeting a bifurcated stress response linked to cancer survival and neurodegenerative or cardiovascular cell death.

AI-driven discovery platform focused on mitochondrial stress-response biology.

Company site states the platform focus and AI-driven discovery approach; no pipeline assets or clinical stage are disclosed.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

OMA1 high-throughput screening assay

exploratory

platform · medium

Enable scalable discovery of OMA1 activators and inhibitors for mitochondrial disease-relevant drug screening.

Cellular OMA1 protease assay using an engineered luciferase reporter targeted to the mitochondrial inner membrane, where reporter signal inversely correlates with OMA1 activity.

Published high-throughput screen reported validation of the reporter assay and identification of both OMA1 activators and inhibitors.

The screen found that kinase inhibitors can activate OMA1 and demonstrated that the assay can detect compounds modulating OMA1 activity.

OMA1 inhibitor discovery program

preclinical

drug program · high

Identify OMA1 inhibitors as potential cytoprotective medicines for disorders influenced by dysfunctional mitochondria, including heart failure and Alzheimer's disease.

Small-molecule drug discovery targeting the mitochondrial inner-membrane protease OMA1 and its OPA1/DELE1 stress-signaling pathway.

Published review describes OMA1 inhibitors as needed drug-like tools and potential medicines, with prior screening efforts reported by multiple groups.

OMA1 inhibition is described as promising based on genetic ablation data in ischemia-reperfusion-related disease models, but potent inhibitors remain a development need.

OPA1 pathway therapeutic strategy for Autosomal Dominant Optic Atrophy

exploratory

research program · medium

Assess therapeutic approaches for Autosomal Dominant Optic Atrophy caused primarily by OPA1 mutations and clarify translational challenges for mitochondrial neurodegeneration.

Review and evaluation of OPA1-pathway therapeutic strategies, including gene augmentation, small molecules, antisense approaches for OPA1 haploinsufficiency, and alternative neuroprotective targets.

2026 publication reviews 25 years from OPA1 gene discovery to therapeutic strategy and notes that antisense therapies targeting OPA1 haploinsufficiency are under human safety evaluation.

The review identifies lack of robust clinical endpoints, variable slow progression, and developmental retinal ganglion cell loss as major challenges for late-stage intervention.

Personalized mitochondrial medicines for age-related diseases

undisclosed

platform · medium

Develop personalized mitochondrial medicines for age-related diseases by targeting a bifurcated stress response linked to cancer survival and neurodegenerative or cardiovascular cell death.

AI-driven discovery platform focused on mitochondrial stress-response biology.

Company site states the platform focus and AI-driven discovery approach; no pipeline assets or clinical stage are disclosed.